CNS Pharmaceuticals (CNSP) Accumulated Expenses (2018 - 2023)
CNS Pharmaceuticals' (CNSP) quarterly Accumulated Expenses came in at $260137.0 in Q2 2023, down 5.94% YoY from $276573.0 in Q2 2022, and down 69.51% on a QoQ basis from $853228.0 in Q1 2023.
CNS Pharmaceuticals (CNSP) Accumulated Expenses (2018 - 2023) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 6 years of Accumulated Expenses data on file, last reported at $260137.0 in Q2 2023.
- Quarterly Accumulated Expenses fell 5.94% year-over-year to $260137.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $260137.0 (down 5.94% YoY) and the FY2022 annual result came in at $828391.0, up 268.26% from the prior year.
- Accumulated Expenses fell to $260137.0 in Q2 2023, from $853228.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $901222.0 in Q3 2021 to a low of $21500.0 in Q4 2019.
- A 5-year average of $390661.8 and a median of $268587.0 in 2020 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2020 — Accumulated Expenses surged 2317.69% — and 2022, when it sank 77.81%.
- Tracing CNSP's Accumulated Expenses over 5 years: stood at $21500.0 in 2019, then surged by 2317.69% to $519804.0 in 2020, then tumbled by 56.72% to $224949.0 in 2021, then jumped by 268.26% to $828391.0 in 2022, then tumbled by 68.6% to $260137.0 in 2023.
- The last three Accumulated Expenses figures came in at $260137.0 (Q2 2023), $853228.0 (Q1 2023), and $828391.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 260,137.00 |
| Mar 31, 2023 | 853,228.00 |
| Dec 31, 2022 | 828,391.00 |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 276,573.00 |
| Mar 31, 2022 | 307,012.00 |
| Dec 31, 2021 | 224,949.00 |
| Sep 30, 2021 | 901,222.00 |
| Jun 30, 2021 | 760,678.00 |
| Mar 31, 2021 | 534,940.00 |
| Dec 31, 2020 | 519,804.00 |
| Sep 30, 2020 | 260,601.00 |
| Jun 30, 2020 | 110,692.00 |
| Mar 31, 2020 | 144,793.00 |
| Dec 31, 2019 | 21,500.00 |
| Sep 30, 2019 | 46,069.00 |
| Dec 31, 2018 | 23,599.00 |